Niagen Bioscience
NAGE (NASDAQ)
Niagen Bioscience, a U.S.-listed penny stock, has garnered attention in the 2026 penny stock roundups despite a challenging performance, showing a 1-year return of -66.08% and a 5-year return of -60.64%. Analysts maintain a positive outlook, with a median 12-month price target set at $10.00, and all rated it as a "Buy," indicating potential for recovery in a volatile market. Investors seeking small-cap opportunities may find value in this stock's future prospects.
Pros:
- Strong 3-year return of 115.19%
- Focus on healthy aging products
Cons:
- Significant negative 1-year and 5-year returns
- High beta of 2.09 indicating volatility
Niagen Bioscience (NAGE) presents a high-risk investment opportunity, particularly suitable for investors with a high tolerance for volatility and a focus on small-cap stocks. Given its significant historical losses, potential investors should carefully consider their risk appetite and investment horizon, while acknowledging the analysts' optimistic outlook for future recovery.